Rhonda Wallen is an Independent Board Director and Advisor to life science companies, leveraging her 25 years of experience to help founders and CEOs develop strategy, complete financings and plan for execution and growth. She was most recently Chief Strategy Officer / EVP of Caresyntax, providers of an end-to-end digital analytics platform for the surgical suite and prior to this, Head of global Corporate Development at Terumo BCT, the $1 billion biomedical division of Terumo Corporation. In this role, as a member of the Global Commercial Leadership Team and its working group on marketing excellence, she led the cross-functional evaluation and negotiation of strategic transactions for blood and cell therapy technologies including a landmark deal that created a significant new line of business in plasma collection. From 2012-16, Ms. Wallen served as the Chief Operating Officer of Andarix Pharmaceuticals, a clinical stage oncology therapeutics company. Also during this time, in consulting roles with Cygnet Venture Management, she served as interim management for senior level business development and marketing functions, working with life science CEOs and founders to validate the strategic direction of emerging growth companies, define key milestones/use of proceeds, and complete corporate financings, helping clients raise over $30 million. As founding CEO of Caveo Therapeutics, a CU spin out company, she raised seed capital and launched a reagent product line, supporting the company’s development of its lead oncology candidates.  Prior to this she was a venture capital investor with Sequel Venture Partners.  Ms. Wallen holds a Bachelor of Science from Stanford University, a Master of Science in Microbiology and a Master of Business Administration from the University of Rochester. She currently serves on the Board of Directors of Ekso Bionics (NASDAQ: EKSO - medical technology for stroke recovery and mobility enhancement); Boulder Community Health ($500M hospital and ambulatory care system); and strategic Advisor to A28 Therapeutics (oncology), Aromyx (industrial biotechnology), and ViuHealth (healthcare data science). 

Rhonda Wallen is an Independent Board Director and Advisor to life science companies, leveraging her 25 years of experience to help founders and CEOs develop strategy, complete financings and plan for execution and growth. She was most recently Chief Strategy Officer / EVP of Caresyntax, providers of an end-to-end digital analytics platform for the surgical suite and prior to this, Head of global Corporate Development at Terumo BCT, the $1 billion biomedical division of Terumo Corporation. In this role, as a member of the Global Commercial Leadership Team and its working group on marketing excellence, she led the cross-functional evaluation and negotiation of strategic transactions for blood and cell therapy technologies including a landmark deal that created a significant new line of business in plasma collection. From 2012-16, Ms. Wallen served as the Chief Operating Officer of Andarix Pharmaceuticals, a clinical stage oncology therapeutics company. Also during this time, in consulting roles with Cygnet Venture Management, she served as interim management for senior level business development and marketing functions, working with life science CEOs and founders to validate the strategic direction of emerging growth companies, define key milestones/use of proceeds, and complete corporate financings, helping clients raise over $30 million. As founding CEO of Caveo Therapeutics, a CU spin out company, she raised seed capital and launched a reagent product line, supporting the company’s development of its lead oncology candidates.  Prior to this she was a venture capital investor with Sequel Venture Partners.  Ms. Wallen holds a Bachelor of Science from Stanford University, a Master of Science in Microbiology and a Master of Business Administration from the University of Rochester. She currently serves on the Board of Directors of Ekso Bionics (NASDAQ: EKSO - medical technology for stroke recovery and mobility enhancement); Boulder Community Health ($500M hospital and ambulatory care system); and strategic Advisor to A28 Therapeutics (oncology), Aromyx (industrial biotechnology), and ViuHealth (healthcare data science).